Guerbet wins PI-CAI Grand Challenge on
detection of prostate cancer
Villepinte, 17 July
2023: Guerbet (FR0000032526 GBT), a
global specialist in contrast media and medical imaging solutions,
is delighted to announce the success of its teams at the PI-CAI
(Prostate Imaging: Cancer Al) Grand Challenge1, an international
challenge organised by a consortium2 of radiology opinion leaders
in prostate imaging, urologists and artificial intelligence
experts, to compare the performance of artificial intelligence
algorithms in the detection of prostate cancer.
Diagnosis of prostate cancer,
a public health issue
The second male cancer according to the WHO,
prostate cancer, with 1.4 million new cases each year worldwide,
accounts for 6.8% of male cancer-related deaths (350,000 deaths per
year). Currently, only 10% to 20% of patients are diagnosed at a
stage where the tumour is resectable.
Magnetic resonance imaging (MRI) plays an
increasingly important role in the early diagnosis of prostate
cancer. The European Association of Urology recommends MRI before
considering a biopsy. However, prostate MRI is difficult to
interpret and requires a good level of expertise to avoid the high
variability of interpretations and diagnostic errors highlighted in
some studies.3
However, thanks to advances in artificial
intelligence, it is possible to develop a machine learning system
that uses supervised learning algorithms trained using large
volumes of medical data from patients with suspected prostate
cancer. By training artificial intelligence on these data, it
becomes possible to create a model capable of detecting the early
signs of prostate cancer.
The PI-CAI Grand Challenge, a
competition to advance the diagnosis of prostate
cancer
The PI-CAI Grand Challenge, launched in November
2022 on the detection of prostate cancer, aims to encourage
technological advances in early diagnosis and accurate detection of
prostate cancer and to evaluate the performance of participants'
artificial intelligence algorithms.
Bringing together more than 320 academic and
industrial teams, including Guerbet, each invited to submit an
artificial intelligence algorithm capable of diagnosing more than
10,000 prostate MRI examinations in order to be compared to
diagnoses of radiologists specialised in prostate imaging.
The PI-CAI Grand Challenge was divided into two
stages. During the first stage, the organisation proposed that the
participating teams train their algorithm on approximately 1,500
data, which was then tested by the organisers on a cohort of
internal data from 1,000 patients. It was at the Annual Meeting of
the Radiological Society of North America (RSNA) 2022 in Chicago
that the Guerbet team was recognised, ranking first and second
according to performance metrics
For the second stage of the challenge, the
organisers proposed that the 5 finalists from the first stage train
their algorithm on a much wider database of 9,100 MRIs in order to
evaluate their performance. Guerbet once again responded
magnificently to the challenge, ranking first in all
categories, according to the results revealed on 10 July
at the Medical Imaging with Deep Learning (MIDL) conference in
Nashville in the United States.
At the same time as this artificial intelligence
challenge, the organisation conducted a multi-centre, multi-reader
study on the same database with the next objective being to compare
radiologists' results to those of algorithms. This second part of
the study will be published next.
"This recognition demonstrates our commitment to
innovation and research to improve the diagnosis and care of
cancer patients. We will continue to invest in advanced technology
solutions to fight this disease, collaborate with healthcare
professionals to further improve our technology and accessibility.
An initial AI prostate cancer algorithm marketing pathway will be
created within the framework of the non-exclusive licensing
agreement signed with Intrasense in the first half of 2024: an
agreement that provides for the marketing of a product
incorporating the Guerbet prostate algorithm during the first
quarter of 2024," says François Nicolas, Senior Vice President,
Research, Development and Innovation, and Chief Digital Officer at
Guerbet.
About Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. That is our purpose. We are a
world leader in medical imaging, offering a complete range of
pharmaceutical products, medical devices and digital and AI
solutions for diagnostic and interventional imaging. Pioneers in
contrast media for 95 years, with more than 2,830 employees
worldwide, we are constantly innovating and devote 8% to 10% of our
revenue to research and development in five centres in France,
Israel and the United States. Guerbet (GBT) is listed on Euronext
Paris (segment B – mid caps) and generated €753 million in revenue
in 2022. For more information, please visit www.guerbet.com.
1 https://pi-cai.grand-challenge.org/
2 The challenge is organised by Radboud
University Medical Center, Ziekenhuis Groep Twente, University
Medical Center Groningen, Norwegian University of Science and
Technology, approved by MIDL, MICCAI, the European Society of
Urogenital Radiology and the European Association of Urology;
sponsored by Amazon Web Services and partially supported by EU
H2020: ProCAncer-I and Health~Holland. The Scientific Advisory
Board is made up of: For the Radiology portion: Prof. Padhani (UK),
Prof. Bonekamp (DE), Prof. Villeirs (BE), Prof. Barentsz (NL),
Prof. Rouvière (FR), Dr. Panebianco (IT); For the Urology portion:
Prof. Bjartell (SE), Prof. Salomon (DE), Dr. Giannarini (IT), Dr.
van den Bergh (NL), Prof. Kasivisvanathan (UK); and for the AI
portion: Prof. Huisman (NL), J. Kalapathy-Cramer (USA), Prof.
Maier-Hein (DE), Prof. Elschot (NO), M. Rusu (USA).3 Rosenkrantz et
al., 2016, Westphalen et al., 2020
Contacts:
Guerbet Claire Lauvernier,
Communications Director +33.6.79.52.11.88 /
claire.lauvernier@guerbet.com
Actifin Michael Scholze,
Press +33.1.56.88.11.14 / michael.scholze@actifin.fr
- 2023 07 17 - GUERBET - AI Challenge
Grafico Azioni Guerbet (EU:GBT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Guerbet (EU:GBT)
Storico
Da Set 2023 a Set 2024